Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadliest cancer worldwide. The primary reasons for this are the lack of early detection methods and targeted therapy. Emerging evidence highlights the metabolic addiction of cancer cells as a potential target to combat PDAC. Oncogenic mutations of KRAS are the most common triggers that drive glucose uptake and utilization via metabolic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Pancreatic Ductal
• Share to Glucose
• Share to Mutation